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Objectives. This study was undertaken to determine whether 
quinidine pharmacodynamics are altered in the presence of left 
ventricular dysfunction. 
Background. Left ventricular function is an independent pre- 
dictor of antiarrhythmic drug efficacy. However, the effects of left 
ventricular dysfunction on the pharmacodynamics ofantiarrhyth- 
mic drugs have not been studied extensively. 
Methods. Signal-averaged electrocardiograms were obtained 
and quinidine plasma concentrations measured uring 24-h quin- 
idine washout in 22 patients. 
Results. Linear quinidine concentration-effect relations were 
observed for QRS and QT intervals corrected for heart rate. The 
slopes of the concentration-effect relation describing changes in 
the corrected QT (QTc) interval were significantly higher in the 
group with left ventricular ejection fraction >0.35 ([mean _+ SD] 
29.5 -+ 11.2 ms//~g per ml) than in the group with a low left 
ventricular ejection fraction (15.7 -+ 9.7 ms/btg per ml, p = 0.001). 
The QRS concentration-effect relations were not different in the 
two groups. A significant linear correlation was observed between 
the slopes of the concentration-effect relations describing changes 
in QTc intervals and left ventricular ejection fraction (r = 0.7, p < 
0.001). Nineteen patients with inducible ventricular tachycardia 
underwent serial electrophysiologic studies for evaluation of quin- 
idine efficacy. Ventricular tachycardia could not be induced 
during quinidine therapy in eight patients. The slopes of the 
quinidine concentration-effect relations for QTc intervals were 
significantly higher in quinidine responders than in nonre- 
sponders (p < 0.05). 
Conclusions. The effects of quinidine on ventricular repolariza- 
tion are linearly related to left ventricular ejection fraction. 
Quinidine concentration-effect relations describing ventricular 
repolarization are associated with antiarrhythmic efficacy in 
patients with ventricular tachycardia. 
(J Am Coil Cardiol 1995;25:989-94) 
Left ventricular function has been reported (1-3) to be an 
independent predictor of antiarrhythmic drug elficacy in pa- 
tients with ventricular tachycardia nd ventricular fibrillation. 
In the setting of left ventricular dysfunction, the effects of 
antiarrhythmic drugs may potentially be modified by underly- 
ing structural heart disease (3-8), electrolyte abnormalities 
(9,10), hemodynamic factors (11,12) or neurohumoral mecha- 
nisms (13,14) associated with heart failure syndrome. The 
antiarrhythmic drug quinidine has been used frequently for the 
management of atrial and ventricular tachyarrhythmias in 
patients with ventricular dysfunction (15,16). Whether quini- 
dine pharmacodynamics are altered in the presence of left 
ventricular dysfunction is unknown. Because quinidine pro- 
longs QRS duration and the QT interval on the surface 
electrocardiogram (ECG), the signal-averaged ECG could be 
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used to study the pharmacodynamic effects of this antiarrhyth- 
mic drug (17,18). Accordingly, the present study sought to 
1) evaluate the effects of left ventricular dysfunction on 
quinidine pharmacodynamics; 2) determine whether the 
signal-averaged ECG could be used to noninvasively study 
antiarrhythmic drug pharmacodynamics; and 3) determine 
whether differences in quinidine pharmacodynamics predict 
suppression of inducible ventricular tachycardia. 
Methods  
Study protocol. Patients receiving quinidine for treatment 
of supraventricular or ventricular tachyarrhythmias were eligi- 
ble for participation in the study. All patients gave written 
informed consent to participate in the study, which was 
approved by the Conjoint Medical Ethics Committee of the 
University of Calgary. Quinidine therapy was initiated with 
quinidine bisulfate, and the dose was titrated to achieve a 
minimal concentration of 10 /xmol/liter or the maximal well 
tolerated ose (19). The quinidine bisulfate dose ranged from 
250 to 750 mg every 8 h. Quinidine was administered at 7 AM 
on the day of study after quinidine therapy had reached steady 
state (->5 half-lives). Patients then underwent a 24-h drug 
washout period. At 0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 h after the 
last quinidine dose, signal-averaged ECGs were obtained, and 
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plasma was collected for quinidine concentration analysis. 
Rhythm strips were obtained simultaneously for documenta- 
tion of the RR interval. 
Signal-averaged ECG intervals. Bipolar X, Y and Z ECG 
leads were recorded and analyzed with the Predictor System 
(Corazonix Corp.). The ECG signal was digitized at a fre- 
quency of 1,000 Hz, and samples were acquired to a noise end 
point of -<0.6 /~V. The unfiltered QRS and QT intervals 
recorded at each sampling time were manually measured by 
one of the investigators (M.M.) who had no knowledge of the 
identity of the patient and the time of ECG recording. The 
QRS duration was measured from the onset of the initial high 
frequency deflection of the QRS complex to the final return of 
the signal to baseline. The terminal component of the QT 
interval was measured as the point where a tangent drawn from 
the T wave intersected the isoelectric line (20). The QT 
interval was corrected for heart rate using the Bazett formula 
(21). The QRS and QT intervals were remeasured bythe same 
investigator in 10 patients on separate days, and intraobserver 
variability was assessed by linear regression analysis. 
Quinidine antiarrhythmic elficacy. Patients with inducible 
sustained ventricular tachycardia during a baseline electro- 
physiologic study underwent a second electrophysiologic study 
for assessment of quinidine antiarrhythmic drug etficacy. The 
stimulation protocol has been described elsewhere (8). Anti- 
arrhythmic etficacy was defined as the failure to induce >15 
repetitive ventricular esponses with the entire ventricular 
pacing protocol. The electrophysiologic study was performed 
5 to 6 h after the last quinidine dose in all but one patient in 
whom the study was performed 2 h after the last quinidine 
dose. The quinidine washout study was performed in these 
patients on the day after their electrophysiologic study. 
Data analysis. Patients were stratified into two groups on 
the basis of left ventricular ejection fraction, which was mea- 
sured by a gated radionuclide angiographic technique: left 
ventricular ejection fraction <0.35 and ->0.35. Quinidine and 
metabolite plasma concentrations were determined using a 
high performance liquid chromatographic assay (22,23). The 
trapezoidal rule was used to calculate the area under the 
plasma drug concentration-time curve. Concentrations of 
quinidine, the contaminant dihydroquinidine and the metabo- 
lite 3-hydroxyquinidine, as well as QRS durations and cor- 
rected QT (QTc) intervals, were compared over time between 
the two groups. Quinidine concentration-effect r lations were 
determined by linear regression analyses (24,25). Multiple 
linear egression analysis was applied to determine the relative 
effects of quinidine on QRS duration and the QTc interval 
(26). The slopes of the concentration-effect relations were 
compared between the two groups and in patients with induc- 
ible sustained ventricular tachycardia who responded to quin- 
idine therapy versus those who did not. 
Statistical analysis, Data are presented as mean value _+ 1 
SD. Comparisons between groups were made using the non- 
paired t test or Fisher exact est, as appropriate. 
Table 1. Clinical Characteristics of 22 Study Patients 
LVEF <0.35 LVEF ->0.35 
(n = 11) (n = 11) 
Age (yr) 64 + 4 62 _+ 12 
Men/women 11/0 7/4 
Cardiac diagnosis 
Coronary artery disease 9 4 
Cardiomyopathy l 2 
Valvular heart disease 1 1 
Primary electrical 0 4 
Presenting arrhythmias 
Ventricular tachycardia 8 8 
Ventricular fibrillation 3 1 
Supraventricular tachycardia 0 2 
IVCD 7 l* 
NYHA functional class 
[-ll 10 2J 
III-IV 0 0 
LVEF 26 _+ 7 52 _+ 4t 
Daily quinidine dose (mg) 1,959 _+ 528 1,639 _+ 636 
*p < 0.05. ~p < 0.01. Data presented are mean value _+ 1 SD or number of 
patients. IVCD = intraventricular conduction delay on 12-1ead electrocardio- 
gram; LVEF - left ventricular ejection fraction; NYHA = New York Heart 
Association. 
Results 
Study patients. The clinical characteristics of the 22 study 
patients are shown in Table 1. Patients with a depressed left 
ventricular ejection fraction more frequently had an intraven- 
tricular conduction delay on the 12 lead ECG (p < 0.05) and 
more frequently had symptoms of congestive heart failure (p < 
0.01) than those with a preserved left ventricular ejection 
fraction. 
Quinidine and metabolite concentrations. Mean quini- 
dine, 3-hydro~quinidine and dihydroquinidine plasma levels 
for the low and high left ventricular ejection fraction groups 
are shown in Figure 1. Quinidine and metabofite concentra- 
tions measured over time and the area under the concentra- 
Figure 1. Quinidine, 3-hydroxyquinidine (3-HO-quinidine) and dihy- 
droquinidine (DH-quinidine) concentrations over time in the low 
(solid symbols, n = 11) and high (open symbols, n = 1l) ejection 
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Table 2. Quinidine Pharmacokinetics and Pharmacodynamics 
LVEF <0.35 LVEF >-0.35 
(n = 11) (n = 11) 
AUC quinidine (tzg/ml'h) 64.7 + 18.1 55.4 +_ 17.8 
AUC 3-HQ 0xg/ml.h) 16.0 _+ 6.8 12.1 + 4.2 
AUC DHQ (~g/ml.h) 3.1 + 3,2 2.7 +_ 3.3 
K~, I quinidine (h 1) 0.0511 - 0,0113 0.{)554 +0.0116 
tV2 quinidine (h) 14.3 +_ 3,4 13.0 + 2.8 
Slope QRS (ms//xg per ml) 451 + 2.32 4.64 _+ 2.74 
(2A0-10.9) (1.07-11.8) 
r value 0.83 "- 0.08 0.74 _+ 0.11 
(0 .68-0 .94)  (0 .59-0 .91)  
Slope QTc (ms/gg per ml) 15.7 + 9.7 29.5 -+ 11.2" 
(3.81-22.8) (9.9-43.2) 
r value 0,68 -+ 0.22 0.76 + 0.08 
(0.38-0.90) (0.62-0.85) 
*p - 0.001. Data presented are mean value _+ I SD (range). AUC = area 
under concentration-time curve; DHQ = dihydroquinidine; 3-HQ = 3-hy- 
droxyquinidine; K~l elimination rate constant; LVEF = left ventricular 
ejection fraction; QTc = corrected QT interval; Slope - slope of linear 
regression a alysis; t]A, - elimination half-life. 
tion-time curves were similar in both groups (Table 2), as was 
the elimination half-life of quinidine. 
Quinidine pharmacodynamics. Intraobserver variability of 
QRS and QT measurements was minimal. The correlation 
coefficient for repeat QRS measurements on a different day 
was 0.87, the slope 1.03 and intercept -5  ms. The correlation 
coefficient for repeat QT measurements was 0.95, the slope 
1.08 and intercept 9 ms. Mean QRS durations and QTc 
intervals over the 24-h washout period are shown in Figure 2. 
The QRS durations and the QTc intervals were greater in the 
low than in the high left ventricular ejection fraction group 
throughout the washout period (p < 0.05). The RR intervals 
were similar during the 24-h quinidine washout in both groups 
Figure 2. Left, QRS durations and corrected QT intervals (QTc) 
during 24-h quinidine washout period for the low (solid circles, n = 
11) and high (open circles, n = 11) left ventricular ejection fraction 
(LVEF) groups. Data are mean value _+ l SD. Right, Relations 
between left ventricular ejection fraction and maximal change (A) in 
QRS duration and corrected QT interval (QTc) measured uring the 
study. 
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and did not change significantly over time (data not shown). 
The maximal change (from peak to trough effect) in QTc 
intervals observed uring the washout phase correlated lin- 
early, whereas that for QRS durations correlated inversely, 
with left ventricular ejection fraction (p < 0.05) (Fig. 2). 
Linear concentration-effect relations. Linear quinidine 
concentration-effect relations for QRS durations were signifi- 
cant (p < 0.05) in all l l  patients with a low left ventricular 
ejection fraction and in 9 of 11 with a high left ventricular 
ejection fraction. For QTc intervals, linear concentration-effect 
relations were significant (p < 0.05) in 9 of i1 patients with a 
low left ventricular ejection fraction and 10 of 11 with a high 
left ventricular ejection fraction (Fig. 3). The slopes of the 
QRS concentration-effect relations were similar in both groups 
(Table 2); however, slopes describing changes in QTc intervals 
were significantly lower in the low than in the high left 
ventricular ejection fraction group (p = 0.001) (Table 2). 
Similar results were observed when 3-hydroxyquinidine con- 
centration-effect relations were analyzed (data not shown). In 
addition, a significant linear correlation was observed between 
the slopes of the quinidine concentration-effect relations de- 
scribing changes in the QTc interval and left ventricular 
ejection fraction (p < 0.001) (Fig. 3). Multiple linear regres- 
sion analysis revealed that quinidine concentration correlated 
independently with QRS duration in six patients in the low 
ejection fraction group and in two in the high ejection group, 
whereas quinidine concentration correlated independently 
with the QTc interval in one patient in the low ejection fraction 
group and in four in the high ejection fraction group. In the 
remaining patients, QRS durations and QTc intervals were not 
independently associated with quinidine concentration 
(p = NS). 
Antiarrhythmic drug efficacy. During quinidine therapy, 
ventricular tachycardia could not be induced during a follow-up 
electrophysiologic study in 2 of 10 patients in the low left 
ventricular ejection fraction group and in 6 of 9 in the high left 
ventricular ejection fraction group (p < 0.07). Quinidine 
concentrations measured at the time of the electrophysiologic 
study were 2.7 + 1.3/zg/ml in the quinidine drug responders 
and 3.5 + 0,7 p,g/ml in the nonresponders (p = NS). The slopes 
of the quinidine concentration-effect relations describing 
changes in the QTc interval were significantly higher in the 
quinidine drug responders (24.9 _+ 10.0 ms/p,g per ml) than in 
nonresponders (15.9 + 7.1 ms/#g per ml, p < 0.05). Differ- 
ences in the slopes of the quinidine concentration-effect rela- 
tions describing changes in ventricular conduction time were 
not observed between drug responders (4.73 _+ 2.17 ms/t~g per 
ml) and nonresponders (5.03 _+ 3.52 ms//zg per ml, p = NS). 
Discuss ion 
Although it is well recognized that left ventricular dysfunc- 
tion is an independent predictor of antiarrhythmic drug inef- 
ficacy (1-3), few studies have evaluated the influence of left 
ventricular dysfunction on the pharmacodynamics of anti- 
arrhythmic drugs. The major findings of the present study are 
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Figure 3. Examples of linear concentration-effect r la- 
tions. Top left, Linear elations between the QRS interval 
and quinidine concentration f rone representative pa-
tient in the high (open circles [slope 3.28 ms/~g per ml, 
r - 0.89, p < 0.001D and one in the low (solid circles 
[slope 3.01 ms//zg per ml, r = 0.90, p < 0.001]) left 
ventricular ejection fraction group. Bottom left, Linear 
relations between the corrected QT interval (QTc) and 
quinidine concentration f rboth patients (high left ven- 
tricular ejection fraction, slope 42.8 ms//xg per ml, r = 
0.84, p = 0.003; low left ventricular ejection fraction, slope 
18.9 ms/~g per ml, r = 0.87, p = 0.001). Right, Relations 
between slopes of the concentration-effect rela ions and 
left ventricular ejection fraction. 
that quinidinc concentration-effect relations are altered in the 
setting of left ventricular dysfunction and that these altered 
concentration-effect relations are associated with antiarrhyth- 
mic drug inefficacy. The effect of quinidine on ventricular 
repolarization and conduction time correlated irectly and 
inversely, respectively, with left ventricular ejection fraction. 
Quinidine pharmacodynamics. Pharmacodynamic odels 
are used to describe the equilibrium relation between concen- 
tration and effect (24). In the present study, linear quinidine 
concentration-effect relations were observed for changes in 
QRS durations and QT intervals. This is not surprising because 
the concentration range evaluated in the present study was 
small and well below the concentration at which 50% of 
maximal effect would be observed, and therefore it fell on the 
linear portion of the concentration-response relation for quin- 
idine (24,25). The slope of the linear regression analysis 
describes the relation between concentration and effect and 
allows comparison of these relations when concentrations vary 
between subjects (24,25). A significant difference in the quin- 
idine concentration-effect relations describing changes in the 
QTc interval was observed between patients with a low and 
those with a high left ventricular ejection fraction. Because the 
slope of the concentration-effect relation is a derived value, 
errors in this calculation might explain the stronger correlation 
observed between slope and left ventricular ejection fraction 
than that observed between the maximal change in the QTc 
interval and left ventricular ejection fraction. However, this 
calculation incorporates differences in plasma quinidine con- 
centrations observed between patients and hence could be a 
stronger measure of the effects of quinidine than changes in 
ECG intervals alone. 
We previously reported (11) similar relations between the 
pharmacodynamics of disopyramide and left ventricular ejec- 
tion fraction. There are four potential explanations for these 
relations: 1) Diastolic stretch is well known to modulate action 
potential duration and ventricular refractory periods (27-29). 
Thus, direct electrophysiologic effects of antiarrhythmic drugs 
may be partially offset by the indirect consequences of the 
effects of the drugs on left ventricular function or by the effects 
of left ventricular dysfunction on cardiac repolarization. 2) 
Increased sympathetic activity or increased circulating cat- 
echolamines associated with clinical congestive heart failure 
might attenuate or reverse the effects of antiarrhythmic drugs, 
including quinidine (30-35). Against this hypothesis, none of 
our patients with a low left ventricular ejection fraction had 
functional class III or IV congestive heart failure symptoms. 
3) Ion channel function may be altered in the setting of 
myocardial disease (4,7,36,37). It is possible that outward 
potassium currents in hypertrophied/failing myocytes may be 
less responsive to the effects of quinidine. 4) Changes in 
plasma protein binding associated with significant left ventric- 
ular function might alter the unbound fraction of quinidine 
and the pharmacodynamics of quinidine (38,39). 
We also demonstrated a negative linear correlation be- 
tween maximal change in QRS duration and left ventricular 
ejection fraction. These findings might be explained by the 
presence of an intraventricular conduction abnormality in 
seven of the patients in the low left ventricular ejection fraction 
group. Diseased, slowly conducting myocardium ight be 
more vulnerable to conduction slowing or blocking by quini- 
dine and other antiarrhythmic drugs because of altered cellular 
electrophysiology or abnormalities of cell-to-cell coupling 
(4,5,7,40,41). 
Quinidine antiarrhythmic efficacy. In patients with ventric- 
ular tachycardia we observed that quinidine concentration- 
effect relations describing changes in ventricular repolarization 
correlated with antiarrhythmic efficacy. We (42) and other 
investigators (43) previously observed that greater antiarrhyth- 
mic drug-induced prolongation ofventricular refractoriness i  
associated with antiarrhythmic efficacy. Patient responders had 
a higher left ventricular ejection fraction, and many did not 
have coronary artery disease. However, future studies will be 
necessary to determine the mechanism(s) of the altered phar- 
macodynamics in the setting of left ventricular dysfunction. 
Potential limitations. The ECG intervals measured in the 
present study reflect global ventricular depolarization and 
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repolarization. Thus, the effects of quinidine on global electro- 
physiologic variables may not reflect he effects of quinidine on 
local tissue involved in a reentrant circuit. As well, the non- 
steady state conditions that existed during the present study 
may not reflect the concentration-effect relations that exist 
during the steady state. Measurement of the QT interval may 
be confounded by the presence of a U wave. In the present 
study we attempted to minimize this problem by selecting a 
lead with one discrete waveform (20). Furthermore, all mea- 
surements were performed by one observer who was unaware 
of patient identity and time of ECG recording. The QT interval 
is most frequently corrected for heart rate using the Bazett 
formula (21). Nevertheless, there is controversy concerning 
which formula is appropriate ocorrect for heart rate (44). The 
use of Bazett formula may cause a substantial overcorrection, 
particularly at slow heart rates. However, in the present study 
heart rates were similar throughout the 24-h washout period in 
both patient groups, thus minimizing this limitation. Moreover, 
the use of the Fridericia formula (44) did not change the 
results (unpublished ata). 
Summary. We observed altered quinidine pharmacody- 
namics in patients with significant left ventricular dysfunction. 
The effects of quinidine on ventricular repolarization directly 
correlate with left ventricular ejection fraction. Furthermore, 
these effects are associated with antiarrhythmic efficacy for 
ventricular tachycardia. However, the mechanism(s) of this 
altered pharmacodynamic response requires further study. 
We thank Linda Ellis, BSc and Heather J. Mathison, BSc for technical assistance 
and Marilyn Devlin for manuscript reparation. 
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